Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
about
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacyA randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophreniaPotential role of the combination of galantamine and memantine to improve cognition in schizophreniaAdjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacologyTransient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist.Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantineCognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders.Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatmentsGoing up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Drug repurposing and emerging adjunctive treatments for schizophrenia.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.Risperidone improves interpersonal perception and executive function in patients with schizophrenia.Role of the cholinesterase inhibitors in the treatment of schizophrenia.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q28297813-F0132242-40DD-47AC-B3A8-6C53F1A79076Q33620592-22276DD2-7C05-47A1-9D9C-2F41941761A7Q33905343-7FAB0217-8C22-4C0E-BB79-CFFB4A80E424Q33933877-25F49344-D6BD-4668-9A22-562A086795A1Q34274859-42A6B831-20C0-495E-9FB8-056C04B9938CQ34315836-49C60A67-E59D-4991-A530-5E9BBE1A37F1Q36097637-0AAAF9A7-487B-48EC-B04E-45E5DCAC413FQ36234254-7F983B5B-6CD5-4D9D-AE65-9CB3C3CFE7FCQ36778677-C0901054-3143-45CA-9759-6A9103890C42Q36813681-83EF2FF8-48D3-4F26-BB2D-21842CED6399Q36883052-30134308-CCD3-4BA8-8123-1EDDBB4DED3AQ37576675-9529ADAD-E09B-4198-9E37-88A06D57F75BQ38171876-200C9CD2-67AE-4C0B-B29E-864DB903DDD3Q38187948-575FCE01-9446-49B2-9CF1-17258A7C942AQ38417631-8ECA5315-E9CF-4A39-A93D-A152911A1442Q38718345-37768960-276B-4E98-ACDD-BBFC9996408DQ39130393-54DD3509-B886-410E-A588-0E7095A377F8Q40571141-D74DC4B9-55F3-4674-8585-ED1DEAC8AFBFQ45377956-5D2A03AE-2304-478A-9CEB-CDFD3609E9DDQ54975082-4BD13E4F-D2CE-48EE-92BD-9FC72719444EQ58561523-DDE918D0-B2DC-4015-9169-6DC362AA1F33
P2860
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@en
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@nl
type
label
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@en
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@nl
prefLabel
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@en
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@nl
P1476
Galantamine augmentation of lo ...... ents in chronic schizophrenia.
@en
P2093
Anzalee Khan
Jean-Pierre Lindenmayer
P304
P356
10.1016/J.SCHRES.2010.08.021
P407
P577
2010-09-17T00:00:00Z